Qun Zhao, Yong Li, Yuan Tian, Zhi-Kai Jiao, Bi-Bo Tan, Xue-Feng Zhao, Zhi-Dong Zhang, Dong Wang, Pei-Gang Yang
Objective:
To compare the efficacy and toxicity of cisplatin plus fluorouracil regimen as adjuvant chemotherapy for advanced gastric cancer.
Methods:
Six hundred thirty-four patients who accepted radical operation were collected from April 2004 to November 2009 in our department, with XELOX regimen 112 cases, mFLO regimen 220 cases and FOLFOX 4 regimen 302 cases. Disease-free survival (DFS) and overall survival (OS) and toxicity as end points were compared among the three groups.
Results:
The median DFS of XELOX, mFLO and FOLFOX 4 regimen were 32.6 months, 25.2 months and 28.8 months respectively (P>0.05), and median OS of XELOX, mFLO and FOLFOX 4 regimen were 43.2 months, 40.7 months and 39.5 months respectively (P>0.05). The three regimens had differences in adverse reactions, hematologic adverse reactions of the three regimens was of no significant difference. But in the non-hematologic adverse reactions, XELOX regimen in the incidence of diarrhea was significantly lower than mFLO regimen and FOLFOX4 regimen (P=0.01<0.05, P=0.037<0.05) the XELOX regimen and FOLFOX4 regimen peripheral neurotoxicity was significantly the lower than mFLO regimen (P=0.001<0.05, P=0.003<0.05).
Conclusions:
There are no statistically significant differences in DFS, OS of XELOX regimen, mFLO regimen and FOLFOX 4 regimen. Combined toxicity, the XELOX program convenient, better tolerated, worthy of further clinical validation and promotion.
